In a study that used a multibiomarker profile including ET-1, NT-proBNP, high-sensitivity cardiac troponin (hs-cTn) I, soluble suppression of tumorigenicity-2 (sST2) and galectin 3 for the clinical assessment of 115 patients with HF, ET-1 was correlated with a more advanced HF, higher pulmonary pressure and reduced right ventricular function. The gene discussed is EDN1; the disease is hydrops fetalis.